Parkinson's Trial NCT07752355
Studying early onset biological markers
- Trial ID
- NCT07752355
- Official Title
- Young Onset Parkinson's Disease Subtypes and Pathogenic Mechanisms
- Goal
- Studying early onset biological markers
- Status
- RECRUITING
- Sponsor
- NYU Langone Health
- Study Type
- OBSERVATIONAL
- Enrollment
- 250 participants
- Conditions
- Young Onset Parkinson Disease, Parkinson Disease
- Registry Record Last Updated
- 2026-08-07 (this month)
- Estimated Commitment
- Moderate commitment estimated from the protocol (based on: invasive procedure). This reflects time and procedures only — confirm details with the study coordinator.
Summary For Families
The team wants to find what biological processes make Parkinson's start younger in some people, so they can better understand causes and find measurable biological signs to guide future treatments and trials. Participants will do one in-person visit with standard questions and a clinical exam, give a blood sample and a small skin sample (a skin punch biopsy) so researchers can study genetic and other biological markers, and in some people they will also collect spinal fluid using a lumbar puncture. Adults 18 and older can join; the younger-onset group needs Parkinson's that began at age 50 or younger, the later-onset group needs Parkinson's that began after age 50, and healthy volunteers must never have had Parkinson's. People with other types of parkinsonism, autoimmune or long-term inflammatory conditions or use of long-term immune-suppressing medicines, pregnancy, or skin problems that prevent a biopsy are not eligible.
Eligibility at a Glance
Key requirements found in this trial's official criteria, in plain language. Only what the listing states is shown; the study team makes the final call.
- Disease stage: Stage 1 on the Hoehn and Yahr scale
- Age when symptoms began: Parkinson's must have started after age 50 (criteria text: "diagnosis of pd confirmed by a movement disorder specialist and with an age of onset after the age of 50 years healthy control cohort: 1")
- Healthy volunteers: Also accepts people without Parkinson's (healthy volunteers) (criteria text: "CT.gov structured field: healthyVolunteers")
Do I Likely Qualify? — Self-Check Dimensions
The trial page offers an interactive self-check built from this trial's parsed criteria. It covers these dimensions; anything the criteria don't state clearly is answered "ask the study coordinator", never assumed.
- This trial requires Hoehn and Yahr stage 1.
Locations
- NYU Langone Health, New York, New York, United States
Making Contact: How to Call This Study Site
Who to ask for
Ask for the study coordinator. Some sites call this person the research coordinator. They are the right person for questions about joining a study. If you reach a front desk or a doctor's office scheduler, ask them to connect you with the research team for this study.
What to say
It is fine to read this out loud, word for word:
Hello, my name is ____. I am calling about a Parkinson's study at your site. The study number is NCT07752355. It is the one about "Studying early onset biological markers". Could I speak with the study coordinator about taking part?
If you are calling for a family member, use their name and mention that you help with their care.
What they will ask you
- The year of diagnosis
- Current medications and their doses
- Other health conditions
- Any procedures already done, such as deep brain stimulation (DBS)
- How far you are able to travel for study visits
- Whether a care partner can come to visits with you
What to have ready
- A written list of current medications and doses
- Your neurologist's name and phone number
- The diagnosis date. The year is enough.
- A recent visit summary from the neurologist, if you have one
What to ask them
- How many visits are there, and how long does each visit take? The listing already answers this: Each participant has one in-person visit at the study center. Ask the coordinator to confirm it still applies.
- Is travel, parking, or my time reimbursed?
- Is there a placebo group, and what is my chance of being in it? The listing already answers this: This is an observational study, so there is no placebo and no experimental treatment is assigned. Researchers observe and collect information while you continue your usual care. Ask the coordinator to confirm it still applies.
- Would I need to stop or pause any of my current medications?
- What happens when the study ends? Could I stay on the treatment if it helps?
What to expect
- Expect to wait a few days for a callback. A week is common. Calling or emailing again after that is fine and normal.
- Many callers do not end up joining. Screening out is common and is not a judgment about you or your health.
- Asking questions commits you to nothing. You can stop the process at any point.
Frequently Asked Questions
- What is this trial testing?
- This trial is studying an experimental treatment. The team wants to find what biological processes make Parkinson's start younger in some people, so they can better understand causes and find measurable biological signs to guide future treatments and trials. Participants will do one in-person visit with standard questions and a clinical exam, give a blood sample and a small skin sample (a skin punch biopsy) so researchers can study genetic and other biological markers, and in some people they will also collect spinal fluid using a lumbar puncture. Adults 18 and older can join; the younger-onset group needs Parkinson's that began at age 50 or younger, the later-onset group needs Parkinson's that began after age 50, and healthy volunteers must never have had Parkinson's. People with other types of parkinsonism, autoimmune or long-term inflammatory conditions or use of long-term immune-suppressing medicines, pregnancy, or skin problems that prevent a biopsy are not eligible.
- Who can participate?
- Participants must be at least 18 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- Being asked to pay to join a trial is a red flag: legitimate trials do not charge a participation fee, and the study treatment and study-specific tests are provided by the trial sponsor. What you might still pay depends on where you live: in the US, routine care you would receive anyway can be billed to you or your insurance; trials in the UK and Canada usually run through public health systems. Travel, parking, and time are real costs, and some trials reimburse them while others do not. Before enrolling, ask the study coordinator to explain in writing what is and is not covered.
- How long does the trial last?
- This trial is estimated to last approximately 4 years and 8 months.
- Can I leave the trial if I change my mind?
- Yes. You can withdraw from any clinical trial at any time, for any reason, without affecting your standard medical care. Trials are voluntary by law. The team may ask if you are willing to do a brief exit visit so they can collect safety information, but you are not obligated.
- Can my spouse or care partner come with me to visits?
- In most cases yes, and it is often encouraged. Care partners can help with notes, questions, and getting home safely after a long visit. Some study assessments do need to happen one on one, but care partners are usually welcome for the rest of the appointment.
- Will I get a placebo in this trial?
- This is an observational study, so there is no placebo and no experimental treatment is assigned. Researchers observe and collect information while you continue your usual care.
- How many visits does this trial involve?
- Each participant has one in-person visit at the study center.
- What procedures are involved in this trial?
- Based on the protocol, this trial involves: Biopsy (invasive); Lumbar puncture (spinal tap) (invasive); Blood draw (minimally invasive); Skin biopsy (minimally invasive); Questionnaires & surveys (non-invasive). Confirm the full schedule with the study coordinator.